Market Access Views & Analysis

Views & Analysis

Market Access

Whatever people think of changes to the UK’s pricing deal, VPAG, judging the difference they make should include monitoring non-submissions to NICE.

Market Access

At ISPOR EU 2025, a cross-stakeholder panel addressed how Joint Clinical Assessment under the EU HTA Regulation is reshaping evidence strategies.

Market Access

A forward glance at new funding vehicles, national strategies, and innovative solutions reshaping the underlying infrastructure of women's care.

Market Access

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

Market Access

The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform

Market Access

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.